Yes, mebendazole (MBZ) can be combined with standard chemotherapy drugs, targeted therapies, hormone treatments, and radiotherapy. In fact, preclinical and clinical literature demonstrates that MBZ frequently acts as a synergistic sensitizer, enhancing the cytotoxicity of conventional antineoplastics, overcoming acquired chemoresistance, and allowing for lower, less toxic drug dosages.
Key Chemotherapy & Combination Partners
Cisplatin (Platinum-Based Chemotherapy):
Ovarian Cancer: In stable cisplatin-resistant ovarian cancer models (OVCAR8CR and SKOV3CR), combining low-dose MBZ with cisplatin restores platinum sensitivity, downregulates survival signaling pathways (ELK/SRF, NF-κB, MYC/MAX), and significantly reduces tumor growth in vivo.
Head & Neck Cancer (HNSCC): MBZ exhibits strong synergistic cytotoxicity with cisplatin in head and neck squamous cell carcinoma cells, suppressing proliferation and promoting differentiation.
Taxanes (Docetaxel / Paclitaxel):
In prostate cancer models, MBZ acts as a clinical candidate that synergizes with docetaxel. Additionally, MBZ downregulates specific β-tubulin isoforms (TUBB1 and TUBB3) that are directly responsible for taxane resistance.
Temozolomide (TMZ):
In glioblastoma multiforme (GBM) and high-grade gliomas, MBZ potentiates temozolomide efficacy. In intracranial animal models, combining MBZ with TMZ significantly extended median survival compared to TMZ alone. Triple combinations with microtubule drugs (such as vinblastine) further ablate TMZ-tolerant glioma cells.
Flutamide (Hormone / Anti-Androgen Therapy):
In prostate cancer cell lines (LNCaP, DU145, PC3), combining MBZ with flutamide produces significantly greater inhibition of cell viability, colony formation, and migration than either agent used independently. This dual therapy increases the BAX/BCL2 mRNA ratio and upregulates E-cadherin while reducing the required dose of flutamide.
Trametinib (MEK Inhibitor):
In refractory NRAS-mutant melanoma models, MBZ synergizes strongly with the MEK inhibitor trametinib, completely blocking MEK1/2 and ERK1/2 phosphorylation and suppressing tumor growth in vivo.
Sulindac (Anti-Inflammatory NSAID):
In preclinical colorectal cancer models (ApcMin/+ mice), combining MBZ with sulindac reduced tumor polyp formation by up to 90% (compared to 56% with MBZ monotherapy).
Anthracyclines & Gemcitabine Immunoconjugates:
In HER2-positive breast cancer (SKBr-3), MBZ demonstrates strong cytotoxicity and synergy when combined with anti-HER2 antibody immunoconjugates carrying anthracyclines or gemcitabine.
Radiotherapy (Radiation Sensitizer):
MBZ acts as a potent radiosensitizer in triple-negative breast cancer (TNBC), malignant meningioma, and glioblastoma by blocking interphase DNA repair protein trafficking (such as Chk2 and Nbs1) to the nucleus.
Why Mebendazole Enhances Other Antineoplastics
Multi-Target Mechanism: Unlike single-target agents, MBZ depolymerizes tubulin at the colchicine site, inhibits multiple oncogenic kinases (VEGFR2, BRAF, MEK, TNIK), and suppresses hypoxia-inducible factors (HIF-1α and HIF-2α).
Reversal of Drug Efflux: MBZ downregulates multi-drug resistance transporters, including P-glycoprotein 1 (P-gp) and MRP1, preventing cancer cells from pumping out co-administered chemotherapy drugs.
References
Chai, J.-Y., Cho, S.-Y., Sohn, W.-M., & Hong, S.-T. (2021). Albendazole and mebendazole as anti-parasitic and anti-cancer agents: An update. The Korean Journal of Parasitology, 59(3), 189–225. https://doi.org/10.3347/kjp.2021.59.3.189
Doudican, N., Rodriguez, A., Osman, I., & Orlow, S. J. (2008). Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells. Molecular Cancer Research, 6(8), 1308–1315. https://doi.org/10.1158/1541-7786.MCR-07-2159
Fattahi, M. R., Taheri, D., Inanloo, S. H., Mirzaei, A., Ghajar, H. A., Reis, L. O., & Aghamir, S. M. K. (2026). Effects of mebendazole and flutamide combination in prostate cancer cell lines: A comprehensive in vitro analysis. Cellular Physiology and Biochemistry, 60, 458–472. https://doi.org/10.33594/000000883
Guerini, A. E., Triggiani, L., Maddalo, M., Bonù, M. L., Frassine, F., Baiguini, A., Alghisi, A., Tomasini, D., Borghetti, P., Pasinetti, N., Bresciani, R., Magrini, S. M., & Buglione, M. (2019). Mebendazole as a candidate for drug repurposing in oncology: An extensive review of current literature. Cancers, 11(9), Article 1284. https://doi.org/10.3390/cancers11091284
Huang, L., Zhao, L., Zhang, J., He, F., Wang, H., Liu, Q., Shi, D., Ni, N., Wagstaff, W., Chen, C., Reid, R. R., Haydon, R. C., Luu, H. H., Shen, L., He, T.-C., & Tang, L. (2021). Antiparasitic mebendazole (MBZ) effectively overcomes cisplatin resistance in human ovarian cancer cells by inhibiting multiple cancer-associated signaling pathways. Aging, 13(16), Article 203232. https://doi.org/10.18632/aging.203232
Joe, N. S., Wang, Y., Oza, H. H., Godet, I., Milki, N., Riggins, G. J., & Gilkes, D. M. (2023). Mebendazole treatment disrupts the transcriptional activity of hypoxia-inducible factors 1 and 2 in breast cancer cells. Cancers, 15(4), Article 1330. https://doi.org/10.3390/cancers15041330
Nygren, P., Fryknäs, M., Ågerup, B., & Larsson, R. (2013). Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer. Journal of Cancer Research and Clinical Oncology, 139(12), 2133–2140. https://doi.org/10.1007/s00432-013-1539-5
Pantziarka, P., Bouche, G., Meheus, L., Sukhatme, V., & Sukhatme, V. P. (2014). Repurposing Drugs in Oncology (ReDO)—mebendazole as an anti-cancer agent. ecancermedicalscience, 8, Article 443. https://doi.org/10.3392/ecancer.2014.443